3566 Women with PCOS Treated with Individualized Homeopathy – A Case Study

Research Head: Dr. Sourabh R. Welling, M.D.
Study Period: 2018-2024
Email: drwelling@welling.co.in

ABSTRACT

Background: Polycystic Ovary Syndrome (PCOS) affects 8-13% of reproductive-aged women globally, presenting complex endocrine and metabolic challenges. Conventional treatments often address symptoms individually without considering the patient’s constitutional totality, leading to partial responses and treatment dissatisfaction.

Objective: To evaluate the effectiveness of individualized homeopathic treatment in managing PCOS symptoms using the CurePlus™ analysis system over a 6-year period.

Methods: A retrospective observational study analyzed 3566 women with confirmed PCOS diagnosis treated with individualized homeopathy. The CurePlus™ analysis system facilitated constitutional assessment, miasmatic evaluation, and precise remedy selection from a database of 2200+ remedies. Treatment protocols emphasized individualization based on symptom totality.

Results: 71.3% of patients showed marked improvement (>75% symptom reduction), with 89.2% experiencing menstrual cycle regulation within 6 months. The most frequently prescribed remedies were Pulsatilla (18.7%), Sepia (16.2%), and Calcarea carbonica (14.3%). Average time to initial improvement was 8.2 weeks.

Conclusion: Individualized homeopathic treatment demonstrated significant efficacy in managing PCOS symptoms, particularly menstrual irregularities and metabolic parameters. The CurePlus™ system enhanced precision in remedy selection, contributing to improved clinical outcomes.

INTRODUCTION

Polycystic Ovary Syndrome represents one of the most prevalent endocrine disorders affecting women of reproductive age, with current epidemiological studies suggesting a global prevalence of 8-13%. The condition manifests through a complex interplay of hormonal imbalances, metabolic dysfunction, and reproductive abnormalities, significantly impacting quality of life across multiple domains. Women with PCOS experience not only physical symptoms such as irregular menstruation, hirsutism, and weight gain but also psychological distress including anxiety, depression, and reduced self-esteem.

The clinical impact of PCOS extends beyond reproductive concerns. Approximately 70% of affected women develop insulin resistance, increasing their risk for type 2 diabetes, cardiovascular disease, and metabolic syndrome. Fertility challenges affect 70-80% of women with PCOS, making it the leading cause of anovulatory infertility. The multisystem nature of this condition necessitates comprehensive treatment approaches that address the individual’s complete symptom profile rather than isolated manifestations.

Conventional medical management typically involves hormonal contraceptives for cycle regulation, metformin for metabolic symptoms, and anti-androgens for hirsutism. While these interventions provide symptomatic relief, they often fail to address the underlying constitutional imbalances and may produce undesirable side effects. Furthermore, the one-size-fits-all approach of conventional treatment protocols may not adequately respond to the heterogeneous presentations of PCOS.

Homeopathic medicine offers a fundamentally different therapeutic approach through its principle of individualization. Rather than prescribing based solely on diagnostic labels, homeopathy considers the patient’s complete symptom picture, including mental, emotional, and physical characteristics. With access to over 2200 remedies, each with distinct symptom profiles, homeopathic practitioners can precisely match remedies to individual constitutional patterns. This personalized approach becomes particularly relevant in PCOS management, where symptom presentations vary significantly among patients.

The primary objective of this study was to evaluate the clinical outcomes of individualized homeopathic treatment in a large cohort of PCOS patients over six years, utilizing the CurePlus™ analysis system to enhance remedy selection precision and track treatment responses systematically.

MATERIALS AND METHODS

Study Design and Setting

This retrospective observational study analyzed clinical data from 3566 women diagnosed with PCOS who received individualized homeopathic treatment at the Welling Homeopathy Clinics between January 2018 and December 2024. The study protocol adhered to ethical guidelines for retrospective research, with patient data anonymized for analysis.

Patient Selection Criteria

Inclusion Criteria:

• Confirmed PCOS diagnosis based on Rotterdam criteria (presence of at least two of: oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound)
• Age range: 18-42 years
• Minimum symptom duration: 6 months
• Willingness to follow prescribed homeopathic treatment protocols
• Regular follow-up capacity for at least 12 months

Exclusion Criteria:

• Concurrent hormonal therapy initiated within 3 months of study enrollment
• Pregnancy or lactation at baseline
• Severe comorbidities requiring immediate conventional intervention
• Adrenal or thyroid disorders mimicking PCOS
• Previous ovarian surgery

CurePlus™ Analysis System Implementation

The CurePlus™ system facilitated comprehensive patient assessment through:

Detailed Symptom Assessment: The system captured 150+ symptom parameters including menstrual patterns, metabolic symptoms, dermatological manifestations, and psychological symptoms. Each symptom was graded for intensity, frequency, and associated modalities.

Constitutional Analysis: Patient constitutions were evaluated based on physical generals, mental characteristics, thermal preferences, food desires/aversions, and sleep patterns. The system’s algorithm weighted constitutional symptoms appropriately for remedy selection.

Miasmatic Evaluation: Predominant miasmatic influences (Psoric, Sycotic, Syphilitic) were identified through family history analysis, disease progression patterns, and characteristic symptom expressions. This evaluation guided remedy selection and potency determination.

Remedy Selection Algorithm: The CurePlus™ system cross-referenced patient symptoms with its database of 2200+ remedies, generating differential remedy options ranked by symptom coverage and constitutional match. Final remedy selection incorporated practitioner expertise and clinical judgment.

Treatment Protocol

Initial consultations lasted 60-90 minutes, involving comprehensive case-taking and baseline assessment. Remedies were prescribed in ascending potencies, typically starting with 30C or 200C based on individual susceptibility. Follow-up consultations occurred monthly for the first six months, then bi-monthly thereafter. Potency adjustments and remedy changes were made based on response patterns documented in the CurePlus™ system.

Outcome Measures

Primary Endpoints:

• Menstrual cycle regularity (cycles between 25-35 days)
• Reduction in clinical hyperandrogenism scores
• Improvement in metabolic parameters (when available)

Secondary Endpoints:

• Fertility outcomes in women attempting conception
• Quality of life scores using PCOS-QOL questionnaire
• Weight/BMI changes
• Patient satisfaction ratings

Statistical Analysis

Data analysis employed SPSS version 26.0. Continuous variables were expressed as mean ± standard deviation or median with interquartile range. Categorical variables were presented as frequencies and percentages with 95% confidence intervals. Treatment response patterns were analyzed using chi-square tests and logistic regression models.

PATIENT DEMOGRAPHICS

Parameter	Value	Notes
Total Patients	3566	All confirmed PCOS diagnosis
Age Range	18-42 years	Reproductive age group
Mean Age ± SD	26.8 ± 5.4 years	Peak incidence in twenties
Gender Distribution	Female: 3566 (100%)	PCOS-specific condition
Duration of Illness	Median: 3.5 years (Range: 0.5-15)	Before homeopathic treatment
Previous Treatments	2847 (79.8%)	Conventional therapy attempted
BMI Categories	Normal: 892 (25.0%), Overweight: 1426 (40.0%), Obese: 1248 (35.0%)	WHO classification
Fertility Concerns	1891 (53.0%)	Active conception attempts

SYMPTOMS PROFILE

Primary Symptoms	Frequency (n)	Percentage (%)	Severity Score*
Irregular Menstruation	3244	91.0	7.8 ± 1.6
Weight Gain/Difficulty Losing Weight	2569	72.1	6.9 ± 2.1
Hirsutism	2140	60.0	6.2 ± 2.3
Acne	1926	54.0	5.8 ± 2.0
Hair Loss/Thinning	1713	48.0	6.5 ± 1.9
Mood Disturbances	1605	45.0	5.4 ± 2.2
Fatigue	1498	42.0	6.1 ± 1.8
Abdominal Bloating	1248	35.0	4.9 ± 2.1

*Scale: 1-10 (1=mild, 10=severe)

RESULTS

Treatment Outcomes

Outcome Category	n	Percentage	95% CI
Marked Improvement (>75%)	2542	71.3%	69.8-72.8
Moderate Improvement (50-75%)	678	19.0%	17.7-20.3
Mild Improvement (25-49%)	249	7.0%	6.2-7.8
No Change (<25%)	97	2.7%	2.2-3.3

Most Frequently Prescribed Remedies

Remedy	Frequency	Percentage	Primary Indication
Pulsatilla	667	18.7%	Irregular menses, weepy disposition, changeable symptoms
Sepia	577	16.2%	Hormonal imbalance, indifference, bearing-down sensation
Calcarea carbonica	510	14.3%	Obesity, profuse menses, chilly constitution
Natrum muriaticum	392	11.0%	PCOS with grief, irregular menses, sun headaches
Lycopodium	321	9.0%	Right-sided ovarian cysts, digestive issues, low confidence
Thuja occidentalis	285	8.0%	Sycotic miasm, ovarian cysts, fixed ideas
Lachesis	249	7.0%	Left-sided symptoms, premenstrual aggravation, jealousy
Sulphur	214	6.0%	Skin problems, hot patient, irregular cycles
Phosphorus	178	5.0%	Anxiety, heavy bleeding, desires cold drinks
Graphites	173	4.8%	Obesity, constipation, delayed menses

Response Timeline Analysis

The average time to initial improvement was 8.2 weeks (range: 2-16 weeks), with menstrual regulation typically occurring within 3-6 months of treatment initiation. Maximum therapeutic benefit was observed at 10.4 months on average. Factors positively affecting response rates included younger age (< 30 years), shorter disease duration (< 2 years), and high treatment compliance (> 90% follow-up attendance).

Notably, 89.2% of patients achieved menstrual cycle regulation (25-35 day cycles) within 6 months. Among the 1891 women actively attempting conception, 743 (39.3%) achieved pregnancy during the study period, with an average time to conception of 14.2 months from treatment initiation.

Metabolic parameters showed significant improvement in patients with available laboratory data. Mean BMI reduction was 2.1 kg/m² in overweight/obese patients. Fasting insulin levels decreased by an average of 35% in patients with documented insulin resistance. Lipid profiles improved in 68% of patients with baseline dyslipidemia.

CASE ILLUSTRATIONS

Case 1: 24-year-old with Classic PCOS Presentation

A 24-year-old software engineer presented with absent menstruation for 8 months, weight gain of 15 kg over 2 years, and moderate facial hair growth. She reported intense sugar cravings, especially premenstrually, and described herself as emotionally sensitive with frequent crying spells. Physical examination revealed central obesity (BMI 29.5) and mild acanthosis nigricans.

Constitutional assessment through CurePlus™ identified key characteristics: warm-blooded, aversion to fatty foods, changeable mood, desire for open air, and symptoms varying from day to day. Based on this totality, Pulsatilla 200C was prescribed.

Within 6 weeks, she experienced her first menstrual period in 8 months. By the fourth month, cycles regulated to 32-day intervals. Weight reduced by 7 kg over 6 months with dietary modifications. Hirsutism scores decreased from 14 to 8 on the Ferriman-Gallwey scale. After 18 months of treatment, she maintained regular cycles and achieved her pre-PCOS weight.

Case 2: 31-year-old with PCOS and Infertility

A 31-year-old teacher sought treatment after 3 years of unsuccessful conception attempts. She had irregular cycles (45-60 days), moderate acne, and thinning hair. Emotionally, she expressed indifference toward loved ones and felt overwhelmed by domestic responsibilities. She reported bearing-down pelvic sensations and felt better with vigorous exercise.

CurePlus™ analysis strongly indicated Sepia, considering her emotional indifference, bearing-down sensation, and improvement from exertion. Sepia 200C was initiated, with potency gradually increased to 1M over 6 months.

Menstrual cycles regulated to 30 days within 4 months. Acne cleared significantly by month 6. Most remarkably, she conceived naturally in the 10th month of treatment and delivered a healthy baby at term. Post-pregnancy, she continued homeopathic treatment and maintained regular cycles.

Case 3: 28-year-old with PCOS and Metabolic Syndrome

A 28-year-old banker presented with PCOS complicated by metabolic syndrome. She had oligomenorrhea (cycles every 70-90 days), truncal obesity (BMI 34.2), insulin resistance, and dyslipidemia. She described intense hunger with trembling if meals were delayed, profuse perspiration, and chronic constipation. Mentally, she was methodical but anxious about financial security.

The symptom totality and constitutional type strongly suggested Calcarea carbonica. Treatment began with Calcarea carbonica 30C daily, later increased to 200C.

Over 12 months, her weight reduced by 18 kg through the combined effect of the remedy and lifestyle modifications. Menstrual cycles became regular at 35-day intervals. Fasting insulin decreased from 28 to 12 μIU/mL. Lipid parameters normalized without conventional medication. She reported increased energy and reduced anxiety about finances.

DISCUSSION

The remarkable improvement rates observed in this study—with 71.3% of patients achieving marked improvement—highlight the potential of individualized homeopathic treatment in PCOS management. These outcomes significantly exceed those typically reported with conventional monotherapy approaches, where improvement rates rarely exceed 50% for comprehensive symptom resolution.

The CurePlus™ system’s contribution to these outcomes cannot be understated. By systematically analyzing over 150 symptom parameters and cross-referencing with 2200+ remedies, the system enabled precise constitutional prescribing that would be challenging to achieve through manual repertorization alone. The algorithm’s ability to weight constitutional symptoms appropriately and identify subtle remedy differentiations likely contributed to the high success rates observed.

The remedy distribution pattern provides interesting insights into PCOS symptomatology from a homeopathic perspective. The predominance of Pulsatilla (18.7%) aligns with the emotional sensitivity and menstrual irregularities common in PCOS. Sepia’s frequency (16.2%) reflects the hormonal disruption and emotional indifference often seen in chronic cases. The high prescription rate of Calcarea carbonica (14.3%) corresponds to the metabolic dysfunction and obesity prevalent in PCOS populations.

Comparing our results with existing homeopathic literature, our success rates align with smaller studies but provide more robust evidence due to our large sample size. A 2019 study by Sharma et al. reported 65% improvement in 120 PCOS patients using individualized homeopathy, while our larger cohort demonstrated even better outcomes, possibly due to the systematic approach enabled by CurePlus™.

When contrasted with conventional treatments, our approach offers several advantages. While metformin typically improves metabolic parameters in 40-50% of patients and oral contraceptives regulate cycles in 70-80%, neither addresses the full spectrum of PCOS symptoms. Our individualized approach achieved comprehensive improvement across multiple symptom domains simultaneously, without the side effects commonly associated with conventional medications.

Study limitations include its retrospective design and lack of a control group. The absence of standardized laboratory monitoring for all patients limits our ability to quantify metabolic improvements comprehensively. Additionally, the 2.7% non-response rate, while low, warrants investigation to identify factors predicting treatment resistance.

The observed therapeutic mechanisms likely involve restoration of hypothalamic-pituitary-ovarian axis function through constitutional rebalancing. While the exact mechanisms of homeopathic remedies remain under investigation, the clinical outcomes suggest genuine biological effects beyond placebo, particularly given the objective improvements in menstrual regulation and fertility outcomes.

CONCLUSION

This comprehensive 6-year study of 3566 women with PCOS demonstrates that individualized homeopathic treatment produces significant clinical improvements across multiple symptom domains. The 71.3% marked improvement rate, coupled with 89.2% achieving menstrual regulation and 39.3% of infertile couples conceiving, provides compelling evidence for homeopathy’s role in PCOS management.

The integration of the CurePlus™ analysis system proved instrumental in achieving these outcomes by enabling precise constitutional prescribing from a vast remedy database. This technological enhancement of classical homeopathic principles represents a significant advance in making individualized treatment more accessible and reproducible.

For practitioners, these findings suggest that homeopathic treatment should be considered as a primary therapeutic option for PCOS, particularly in patients seeking comprehensive symptom resolution without conventional medication side effects. The average treatment duration of 10-12 months for maximum benefit should be communicated to patients to set appropriate expectations.

Future research should focus on prospective controlled trials, investigation of specific remedy responses in PCOS subtypes, and exploration of combining homeopathic treatment with lifestyle interventions. Long-term follow-up studies would valuable to assess treatment sustainability and prevention of PCOS-related complications.

The role of individualized prescribing cannot be overemphasized—the success of homeopathic treatment in PCOS depends critically on matching the remedy to the patient’s complete symptom picture rather than prescribing based solely on the diagnosis.

WELLING CLINICAL HIGHLIGHTS

Key Success Metrics

• 71.3% of patients achieved marked improvement (>75% symptom reduction)
• 89.2% experienced menstrual cycle regulation within 6 months
• 39.3% of women attempting conception achieved pregnancy
• 8.2 weeks average time to initial improvement
• 2.1 kg/m² mean BMI reduction in overweight/obese patients

Most Effective Remedies for PCOS

1. Pulsatilla – Changeable symptoms, emotional sensitivity
2. Sepia – Hormonal imbalance, indifference
3. Calcarea carbonica – Metabolic dysfunction, obesity
4. Natrum muriaticum – Emotional suppression, irregular menses
5. Lycopodium – Right-sided cysts, digestive issues

Treatment Duration Guidelines

• Initial improvement: 6-12 weeks
• Menstrual regulation: 3-6 months
• Maximum benefit: 10-12 months
• Maintenance phase: Ongoing constitutional support

Patient Satisfaction Metrics

• Overall satisfaction rate: 94.2%
• Would recommend to others: 96.8%
• Preferred over previous conventional treatment: 87.3%
• Reported improved quality of life: 91.5%

CurePlus™ System Advantages

• Analyzes 150+ symptom parameters systematically
• Access to 2200+ remedy database
• Precise constitutional matching algorithms
• Tracks treatment response objectively
• Facilitates consistent prescribing across practitioners
• Enables large-scale outcome analysis